Vertex Pharmaceuticals Incorporated (VRTX) Set to Announce Quarterly Earnings on Wednesday
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is scheduled to be issuing its quarterly earnings data after the market closes on Wednesday, October 25th. Analysts expect the company to announce earnings of $0.40 per share for the quarter.
Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.39 EPS for the quarter, topping analysts’ consensus estimates of $0.06 by $0.33. Vertex Pharmaceuticals had a return on equity of 4.64% and a net margin of 12.05%. The business had revenue of $544.10 million during the quarter, compared to analysts’ expectations of $489.95 million. During the same quarter last year, the company posted $0.24 earnings per share. Vertex Pharmaceuticals’s quarterly revenue was up 26.1% on a year-over-year basis. On average, analysts expect Vertex Pharmaceuticals to post $0.49 EPS for the current fiscal year and $1.98 EPS for the next fiscal year.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) opened at 154.63 on Monday. The company has a market cap of $38.99 billion, a PE ratio of 148.54 and a beta of 1.73. The company’s 50-day moving average price is $154.14 and its 200-day moving average price is $137.63. Vertex Pharmaceuticals Incorporated has a 12-month low of $71.46 and a 12-month high of $167.85.
In other news, CEO Jeffrey M. Leiden sold 11,063 shares of the firm’s stock in a transaction on Monday, July 31st. The shares were sold at an average price of $152.81, for a total transaction of $1,690,537.03. Following the sale, the chief executive officer now owns 268,455 shares in the company, valued at approximately $41,022,608.55. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Paul M. Silva sold 860 shares of the firm’s stock in a transaction on Monday, July 31st. The shares were sold at an average price of $152.99, for a total transaction of $131,571.40. Following the sale, the senior vice president now owns 17,494 shares in the company, valued at approximately $2,676,407.06. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 43,748 shares of company stock worth $6,734,021. Corporate insiders own 1.80% of the company’s stock.
A number of equities research analysts have issued reports on the stock. Stifel Nicolaus upped their price objective on shares of Vertex Pharmaceuticals from $130.00 to $154.00 and gave the stock a “buy” rating in a research report on Tuesday, July 18th. Robert W. Baird reaffirmed an “outperform” rating and issued a $171.00 price objective (up from $136.00) on shares of Vertex Pharmaceuticals in a research report on Friday, July 21st. Cowen and Company reaffirmed a “market perform” rating and issued a $105.00 price objective on shares of Vertex Pharmaceuticals in a research report on Thursday, July 6th. UBS AG downgraded shares of Vertex Pharmaceuticals from a “buy” rating to a “neutral” rating and upped their price objective for the stock from $135.00 to $174.00 in a research report on Wednesday, July 19th. They noted that the move was a valuation call. Finally, J P Morgan Chase & Co set a $175.00 price objective on shares of Vertex Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, July 19th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, twenty-three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $167.25.
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.
Receive News & Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.